Pharmaceutical

(Re-correction) "Reference Data for FY2025 Consolidated Financial Results"

(Re-correction) "Reference Data for FY2025 Consolidated Financial Results"

Daiichi Sankyo Company, LimitedAugust 7, 20264

(Re-correction) "Reference Data for FY2025 Consolidated Financial Results"

About this update from Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited (4568) Press Release View Attachment

View stock analysis, news, and events for Daiichi Sankyo Company, Limited

More from Daiichi Sankyo Company, Limited

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients...

September 13, 2026

Daiichi Sankyo : Receives Favorable Judgment in Damage Claim Filed by NTK

September 10, 2026

All Daiichi Sankyo Company, Limited news →